Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of “Hold” by Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $19.00.

A number of analysts have recently weighed in on the stock. Piper Jaffray Companies raised their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, October 16th. Deutsche Bank set a $21.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 25th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a research report on Wednesday, January 24th. They set a “neutral” rating and a $20.00 price target for the company.

Several hedge funds have recently added to or reduced their stakes in the company. Alliancebernstein L.P. grew its position in shares of Halozyme Therapeutics by 53.7% during the fourth quarter. Alliancebernstein L.P. now owns 271,654 shares of the biopharmaceutical company’s stock worth $5,504,000 after buying an additional 94,960 shares in the last quarter. Lombard Odier Asset Management Switzerland SA lifted its stake in Halozyme Therapeutics by 62.3% during the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 324,500 shares of the biopharmaceutical company’s stock worth $6,574,000 after purchasing an additional 124,500 shares during the last quarter. Bogle Investment Management L P DE bought a new position in Halozyme Therapeutics during the fourth quarter worth $10,622,000. Geode Capital Management LLC lifted its stake in Halozyme Therapeutics by 8.5% during the fourth quarter. Geode Capital Management LLC now owns 1,251,161 shares of the biopharmaceutical company’s stock worth $25,348,000 after purchasing an additional 98,045 shares during the last quarter. Finally, First Republic Investment Management Inc. lifted its stake in Halozyme Therapeutics by 7.1% during the fourth quarter. First Republic Investment Management Inc. now owns 45,000 shares of the biopharmaceutical company’s stock worth $912,000 after purchasing an additional 3,000 shares during the last quarter. 82.72% of the stock is owned by institutional investors and hedge funds.

Shares of Halozyme Therapeutics (NASDAQ HALO) remained flat at $$17.84 during trading hours on Tuesday. 395,057 shares of the company were exchanged, compared to its average volume of 1,274,889. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.46 and a quick ratio of 3.37. Halozyme Therapeutics has a 52-week low of $11.41 and a 52-week high of $21.13. The company has a market cap of $2,444.27, a price-to-earnings ratio of -26.23 and a beta of 1.99.

ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of “Hold” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/halozyme-therapeutics-inc-halo-given-consensus-rating-of-hold-by-brokerages.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply